FORBES : YA SON TRES LOS FÁRMACOS APROBADOS PARA EL TRATAMIENTO DE PACIENTES HOSPITALIZADOS CON COVID ... REMDESIVIR ( BY GILEAD ) , BARICITINIB ( OLUMIANT BY LILLY ) Y TOCILIZUMAB ( ACTEMRA BY ROCHE/GENENTECH ) .

 

How Recently Approved Tocilizumab Treats Covid-19 .

The Treatment of Severe Covid-19 has proven difficult over the past three years, illustrated most clearly by the lack of approved drugs to treat the disease. 

Recently, the Food and Drug Administration has just its third fully approved treatment, joining Baricitinib and Remdesivir.

Baricitinib is approved for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

 In contrast, Remdesivir is approved for all patients with mild-to-moderate COVID-19 who are at high risk for progression to severe COVID-19, including hospitalization or death .

Tocilizumab, branded Actemra by pharmaceutical company Genentech, is a monoclonal antibody now approved for treating Covid-19 in hospitalized adult patients who receive systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), akin to Barcitinib. 

All treatments to this point of the pandemic were only temporarily approved via emergency use authorization. 

In a previous article, we discussed the antibody’s discovery and mechanism of action.

 Here we discuss how Tocilizumab treats those suffering from moderate to severe Covid-19 . ...